A comparison of the predictive power for survival in gliomas provided by MIB-1, bromodeoxyuridine and proliferating cell nuclear antigen with histopathologic and clinical parameters

Paul E. Mckeever, Donald (Don) Ross, Myla S. Strawderman, James A. Brunberg, Harry S. Greenberg, Larry Junck

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

The purpose of this prospective study of 65 patients was to compare side by side the predictive power for survival of (a) MIB-1, (b) bromodeoxyuridine (BUDR), and (c) proliferating cell nuclear antigen (PCNA). They were compared (a) with each other, (b) with several clinical predictors, and (c) with histopathologic grade under actual clinical biopsy conditions in a study of 1993 World Health Organization (WHO) grade II to IV adult supratentorial gliomas. There was a strong positive relationship between MIB-1 and BUDR by Spearman Rank correlation. In univariate analysis, MIB-1 (logrank p = 0.061 was more predictive of survival than BUDR or PCNA. Longer survivors were distinguished from others by the lowest MIB-1 labeling indices (LI ≤ 2.5%) better than by the lowest histopathologic grade. However, histopathologic grades were highly predictive among the entire group (logrank p <0.0001). Young age (p <0.0001) and high Karnofsky performance status (p <0.0001) were the clinical factors most predictive of longer survival. Female gender correlated with longer survival (logrank p = 0.02). In multivariate Cox proportional hazards models, age. Karnofsky performance status, and histopathologic grading remained statistically significant after full reduction of the model. We conclude that Ki-67 measured by MIB-1 monoclonal antibody was superior to other markers of proliferation. When all factors are considered simultaneously over all 3 grades of malignancy, greatest predictive power resides in histopathologic grade and clinical variables. MIB-1 is expected to be most important in cases where clinical or histopathologic factors are ambiguous or where they cannot be fully assessed.

Original languageEnglish (US)
Pages (from-to)798-805
Number of pages8
JournalJournal of Neuropathology and Experimental Neurology
Volume56
Issue number7
StatePublished - Jul 1997
Externally publishedYes

Fingerprint

Proliferating Cell Nuclear Antigen
Bromodeoxyuridine
Glioma
Karnofsky Performance Status
Survival
Proportional Hazards Models
Survivors
Prospective Studies
Biopsy
Neoplasms

Keywords

  • Astrocytoma
  • BUDR
  • Glioma
  • Karnofsky
  • Ki-67
  • MIB-1
  • PCNA

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Neuroscience(all)

Cite this

A comparison of the predictive power for survival in gliomas provided by MIB-1, bromodeoxyuridine and proliferating cell nuclear antigen with histopathologic and clinical parameters. / Mckeever, Paul E.; Ross, Donald (Don); Strawderman, Myla S.; Brunberg, James A.; Greenberg, Harry S.; Junck, Larry.

In: Journal of Neuropathology and Experimental Neurology, Vol. 56, No. 7, 07.1997, p. 798-805.

Research output: Contribution to journalArticle

@article{7fdd2238ec38448f87fb07d03476ab54,
title = "A comparison of the predictive power for survival in gliomas provided by MIB-1, bromodeoxyuridine and proliferating cell nuclear antigen with histopathologic and clinical parameters",
abstract = "The purpose of this prospective study of 65 patients was to compare side by side the predictive power for survival of (a) MIB-1, (b) bromodeoxyuridine (BUDR), and (c) proliferating cell nuclear antigen (PCNA). They were compared (a) with each other, (b) with several clinical predictors, and (c) with histopathologic grade under actual clinical biopsy conditions in a study of 1993 World Health Organization (WHO) grade II to IV adult supratentorial gliomas. There was a strong positive relationship between MIB-1 and BUDR by Spearman Rank correlation. In univariate analysis, MIB-1 (logrank p = 0.061 was more predictive of survival than BUDR or PCNA. Longer survivors were distinguished from others by the lowest MIB-1 labeling indices (LI ≤ 2.5{\%}) better than by the lowest histopathologic grade. However, histopathologic grades were highly predictive among the entire group (logrank p <0.0001). Young age (p <0.0001) and high Karnofsky performance status (p <0.0001) were the clinical factors most predictive of longer survival. Female gender correlated with longer survival (logrank p = 0.02). In multivariate Cox proportional hazards models, age. Karnofsky performance status, and histopathologic grading remained statistically significant after full reduction of the model. We conclude that Ki-67 measured by MIB-1 monoclonal antibody was superior to other markers of proliferation. When all factors are considered simultaneously over all 3 grades of malignancy, greatest predictive power resides in histopathologic grade and clinical variables. MIB-1 is expected to be most important in cases where clinical or histopathologic factors are ambiguous or where they cannot be fully assessed.",
keywords = "Astrocytoma, BUDR, Glioma, Karnofsky, Ki-67, MIB-1, PCNA",
author = "Mckeever, {Paul E.} and Ross, {Donald (Don)} and Strawderman, {Myla S.} and Brunberg, {James A.} and Greenberg, {Harry S.} and Larry Junck",
year = "1997",
month = "7",
language = "English (US)",
volume = "56",
pages = "798--805",
journal = "American Journal of Psychotherapy",
issn = "0002-9564",
publisher = "Lippincott Williams and Wilkins",
number = "7",

}

TY - JOUR

T1 - A comparison of the predictive power for survival in gliomas provided by MIB-1, bromodeoxyuridine and proliferating cell nuclear antigen with histopathologic and clinical parameters

AU - Mckeever, Paul E.

AU - Ross, Donald (Don)

AU - Strawderman, Myla S.

AU - Brunberg, James A.

AU - Greenberg, Harry S.

AU - Junck, Larry

PY - 1997/7

Y1 - 1997/7

N2 - The purpose of this prospective study of 65 patients was to compare side by side the predictive power for survival of (a) MIB-1, (b) bromodeoxyuridine (BUDR), and (c) proliferating cell nuclear antigen (PCNA). They were compared (a) with each other, (b) with several clinical predictors, and (c) with histopathologic grade under actual clinical biopsy conditions in a study of 1993 World Health Organization (WHO) grade II to IV adult supratentorial gliomas. There was a strong positive relationship between MIB-1 and BUDR by Spearman Rank correlation. In univariate analysis, MIB-1 (logrank p = 0.061 was more predictive of survival than BUDR or PCNA. Longer survivors were distinguished from others by the lowest MIB-1 labeling indices (LI ≤ 2.5%) better than by the lowest histopathologic grade. However, histopathologic grades were highly predictive among the entire group (logrank p <0.0001). Young age (p <0.0001) and high Karnofsky performance status (p <0.0001) were the clinical factors most predictive of longer survival. Female gender correlated with longer survival (logrank p = 0.02). In multivariate Cox proportional hazards models, age. Karnofsky performance status, and histopathologic grading remained statistically significant after full reduction of the model. We conclude that Ki-67 measured by MIB-1 monoclonal antibody was superior to other markers of proliferation. When all factors are considered simultaneously over all 3 grades of malignancy, greatest predictive power resides in histopathologic grade and clinical variables. MIB-1 is expected to be most important in cases where clinical or histopathologic factors are ambiguous or where they cannot be fully assessed.

AB - The purpose of this prospective study of 65 patients was to compare side by side the predictive power for survival of (a) MIB-1, (b) bromodeoxyuridine (BUDR), and (c) proliferating cell nuclear antigen (PCNA). They were compared (a) with each other, (b) with several clinical predictors, and (c) with histopathologic grade under actual clinical biopsy conditions in a study of 1993 World Health Organization (WHO) grade II to IV adult supratentorial gliomas. There was a strong positive relationship between MIB-1 and BUDR by Spearman Rank correlation. In univariate analysis, MIB-1 (logrank p = 0.061 was more predictive of survival than BUDR or PCNA. Longer survivors were distinguished from others by the lowest MIB-1 labeling indices (LI ≤ 2.5%) better than by the lowest histopathologic grade. However, histopathologic grades were highly predictive among the entire group (logrank p <0.0001). Young age (p <0.0001) and high Karnofsky performance status (p <0.0001) were the clinical factors most predictive of longer survival. Female gender correlated with longer survival (logrank p = 0.02). In multivariate Cox proportional hazards models, age. Karnofsky performance status, and histopathologic grading remained statistically significant after full reduction of the model. We conclude that Ki-67 measured by MIB-1 monoclonal antibody was superior to other markers of proliferation. When all factors are considered simultaneously over all 3 grades of malignancy, greatest predictive power resides in histopathologic grade and clinical variables. MIB-1 is expected to be most important in cases where clinical or histopathologic factors are ambiguous or where they cannot be fully assessed.

KW - Astrocytoma

KW - BUDR

KW - Glioma

KW - Karnofsky

KW - Ki-67

KW - MIB-1

KW - PCNA

UR - http://www.scopus.com/inward/record.url?scp=0030949269&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030949269&partnerID=8YFLogxK

M3 - Article

VL - 56

SP - 798

EP - 805

JO - American Journal of Psychotherapy

JF - American Journal of Psychotherapy

SN - 0002-9564

IS - 7

ER -